◎ 국내학회지 발표논문
1. A Case of Gallbladder Actinomycosis. 감염과 화학요법 35:337-340, 2003

2. Biliary stricture associated with common bile duct stone caused by endoscopic snare papillectomy of ampullary adenoma. 대한소화기내시경학회지 23:259-262, 2001

3. A case of acute recurrent pancreatitis whose etiology was diagnosed by endoscopic ultrasonography. 대한소화기내시경학회지 27:258-262, 2003

4. A case of lymphomatoid contact dermatitis caused by garlic. 천식 및 알레르기 23:548-52, 2003

5. A case of primary pure cholesterol hepatolithiasis. 대한소화기내시경학회지 26:448-453, 2003

◎ 국제학회지 발표논문
1. Kim JH, Kim HS, Sung CW, Kim KJ, Kim CH, Lee KY. Docetaxel, gemcitabine, and cisplatin administered for non-small cell lung cancer during the first and second trimester of an unrecognized pregnancy. Lung Cancer 2008;59:270-273

2. Kim JH, Kim HS, Kwon JH, Park S, Kim HY, Jung JY, Kim HJ, Song HH, Lee GW, Lee SI, Gong SJ, Lee JA, Kim KJ, Zang DY. Systemic chemotherapy after cranial irradiation in patients with brain metastases from non-small cell lung cancer: A retrospective study. Lung Cancer 2009;63:405-409

3. Lee Y, Uhm JE, Lee HY, Park MJ, Kim H, Oh SJ, Jang JH, Kim K, Jung CW, Ahn YC, Park K, Ko YH, Kim WS. Clinical features and prognostic factors of patients Clinical features and prognostic factors of patients with “peripheral T cell lymphoma, unspecified” Annals of Hematology 2009;88:111-119

4. Kim JH, Kim HS, Choi JS, Lee KM, Shin YC, Ahn BM, Choi DR, Kwon JH, Park S, Kim HY, Jung JY, Kim HJ, Song HH, Zang DY. Bilateral subdural hemorrhage as a possible adverse event of gefitinib in a patient with non-small cell lung cancer. Lung Cancer 2009;64:121–123

5. Zang DY, Yang DH, Kim MJ, Jang KM, Hwang SW, Yoo KS, Han T, Kim HY, Kim HJ, Kwon JH, Song HH, Park S, Jung JY, Kim HS, Kim JH. Dose-finding study of docetaxel, oxaliplatin, and S-1 for patients with advanced gastric cancer. Cancer Chemother Pharmacol. 2009 Oct;64(5):877-83.

6. Kim HS, Park MJ, Uhm JE, Lee Y, Lee HY, Kang EM, Lee J, Park SH, Park JO, Lim HY, Kang WK, Park YS. A phase I trial of S-1 with oxaliplatin in patients with relapsed and metastatic colorectal cancer. Int J Colorectal Dis. 2009 Nov;24(11):1311-6.

7. Lim do H, Kim HS, Park YS, Lee J, Park SH, Lim HY, Ji SH, Park MJ, Yi SY, An JY, Sohn TS, Noh JH, Bae JM, Kim S, Park CK, Kang WK. Metastatic lymph node in gastric cancer; is it a real distant metastasis? BMC Cancer. 2010 Jan 29;10:25.

8. Kim HS, Park YH, Lee J, Ahn JS, Kim J, Shim YM, Kim JH, Park K, Han J, Ahn MJ. Clinical impact of phosphorylated signal transducer and activator of transcription 3, epidermal growth factor receptor, p53, and vascular endothelial growth factor receptor 1 expression in resected adenocarcinoma of lung by using tissue microarray. Cancer. 2010 Feb 1;116(3):676-85.

9. Kwon JH, Kim JH, Lee JA, Shin HC, Kim HJ, Song HH, Jung JY, Kim HY, Choi DR, Kim HS, Park YI, Zang DY. Phase II study with fractionated schedule of docetaxel and cisplatin in patients with advanced non-small cell lung cancer. Cancer Chemother Pharmacol. 2010 Oct;66(5):889-97. Epub 2010 Jan 21.

10. Kim HS, Lee GW, Kim JH, Kim HY, Kwon JH, Song HH, Kim HJ, Jung JY, Jang G, Choi DR, Park SM, Shin TR, Lee HS, Zang DY. A phase II study of pemetrexed and carboplatin as a salvage therapy for platinum-pretreated patients with non-small cell lung cancer. Lung Cancer. 2010 Oct;70(1):71-6. Epub 2010 Jan 21.

11. Lim do H, Park SH, Park KW, Kang JH, Oh SY, Hwang IG, Kwon JM, Lee SC, Lee HY, Kim HS, Lim HY, Kang WK. Retrospective analyses of cisplatin-based doublet combination chemotherapy in patients with advanced gastric cancer. BMC Cancer. 2010 Oct 26;10:583.

12. Kim JH, Kim HS, Choi DR, Jang G, Kwon JH, Kim HY, Jung JY, Kim HJ, Song HH, Shin YH, Jung SY, Kim BC, Zang DY. A phase II study of mitomycin-C and S-1 as third-line chemotherapy in patients with advanced colorectal cancer. Oncol Lett. 2011 Nov;2(6):1253-1256. Epub 2011 Jul 27.

13. Kim HS, Kim JH, Kim HJ, Jang HJ, Kim JB, Kim JW, Jung SY, Kim BC, Yang DH, Park S, Kim KJ, Lee SI, Zang DY. Oxaliplatin, 5-fluorouracil and leucovorin (modified FOLFOX-6) as first-line chemotherapy for advanced gastric cancer patients with poor performance status. Oncol Lett. 2012 Feb;3(2):425-428. Epub 2011 Nov 25.

14. Kim JH, Kim HS, Han AR, Moh IH, Chung DC, Choi DR, Jang HJ, Kim JB, Yang DH, Lee SI, Zang DY. Irinotecan, leucovorin and 5-fluorouracil (modified FOLFIRI) as salvage chemotherapy for frail or elderly patients with advanced gastric cancer. Oncol Lett. 2012 Oct;4(4):751-754.

15. Kwon JH, Oh SY, Chisholm G, Lee JA, Lee JJ, Park KW, Nam SH, Song HH, Lee K, Zang DY, Kim HY, Choi DR, Kim HJ, Kim JH, Jung JY, Jang G, Kim HS, Won JY, Bruera E. Predictors of high score patient-reported barriers to controlling cancer pain: a preliminary report. Support Care Cancer. 2013 Apr;21(4):1175-83.

16. Kim HS, Kim JH, Kim B, Choi HC, Kwon JH, Choi DR. Phase II study of weekly carboplatin and irinotecan as first-line chemotherapy for patients with advanced non-small cell lung cancer. Cancer Chemother Pharmacol. 2013 Jun;71(6):1591-7.

17. Jang G, Song HH, Park KU, Kim HS, Choi DR, Kwon JH, Kim HY, Han B, Kim JH, Jung JY, Kim HJ,Zang DY. A Phase II Study to Evaluate the Efficacy of Ramosetron, Aprepitant, and Dexamethasone in Preventing Cisplatin-Induced Nausea and Vomiting in Chemotherapy-Naïve Cancer Patients. Cancer Res Treat. 2013 Sep;45(3):172-7.

18. Song H, Han B, Park CK, Kim JH, Jeon JY, Kim IG, Kim HJ, Jung JY, Kim JH, Kwon JH, Jang G, Kim HY, Kim HS, Choi DR, Zang DY. Phase II trial of gemcitabine and S-1 for patients with advanced pancreatic cancer. Cancer Chemother Pharmacol. 2013 Oct;72(4):845-52.

19. Kim HS, Kim HJ, Kim SY, Kim TY, Lee KW, Baek SK, Kim TY, Ryu MH, Nam BH, Zang DY. Second-line chemotherapy versus supportive cancer treatment in advanced gastric cancer: a meta-analysis. Ann Oncol. 2013 Nov;24(11):2850-4.